Baseline characteristics
| Variable | All (n=472) | Febuxostat group (n=236) | Control group (n=236) | SMD |
| Age (years) | 71.0 (63.0–77.0) | 70.5 (63.0–76.0) | 71.0 (62.0–78.0) | 0.039 |
| Male | 379 (80.3%) | 188 (79.7%) | 191 (80.9%) | 0.032 |
| Body mass index (kg/m2) | 24.6 (22.4–27.0) | 24.2 (22.2–26.7) | 24.6 (22.8–27.3) | 0.058 |
| Hypertension | 419 (88.8%) | 209 (88.6%) | 210 (89.0%) | 0.013 |
| Diabetes | 169 (35.8%) | 84 (35.6%) | 85 (36.0%) | 0.009 |
| Dyslipidaemia | 283 (60.0%) | 141 (59.7%) | 145 (60.2%) | 0.009 |
| Current smoking | 51 (10.8%) | 27 (11.4%) | 24 (10.2%) | 0.041 |
| Prior myocardial infarction | 58 (12.3%) | 32 (13.6%) | 26 (11.0%) | 0.077 |
| Prior stroke | 26 (5.5%) | 14 (5.9%) | 12 (5.1%) | 0.037 |
| Prior heart failure | 77 (16.3%) | 40 (16.9%) | 37 (15.7%) | 0.034 |
| eGFR (mL/min/1.73 m2) | 56.9 (45.5–66.5) | 55.0 (44.8–65.9) | 54.8 (46.6–66.7) | 0.071 |
| Serum uric acid (mg/dL) | 7.6 (7.1–8.2) | 7.6 (7.2–8.2) | 7.6 (7.1–8.3) | 0.027 |
| Medications at baseline | ||||
| ACE-I | 53 (11.2%) | 25 (10.6%) | 28 (11.9%) | 0.040 |
| ARB | 269 (57.0%) | 131 (55.5%) | 138 (58.5%) | 0.060 |
| Calcium channel blocker | 250 (53.0%) | 130 (55.1%) | 120 (50.8%) | 0.085 |
| β-blocker | 180 (38.1%) | 85 (36.0%) | 95 (40.3%) | 0.087 |
| Diuretic | 137 (29.0%) | 69 (29.2%) | 68 (28.8%) | 0.009 |
| Statin | 233 (49.4%) | 115 (48.1%) | 121 (51.3%) | 0.076 |
Values are expressed as median (IQR) or number (%).
ACE-I, ACE inhibitor; ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate; SMD, standardised mean difference.